ITeos Therapeutics
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of highly differentiated immuno-oncology therapeutics for patients. The company specializes in targeted immunotherapies for cancer, leveraging deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates aimed at improving clinical benefits in oncology. With a focus on innovative science-driven work, iTeos develops therapies targeting key cancer resistance mechanisms, including TIGIT, ENT1, and TREM2, with ongoing clinical trials for various indications. The company emphasizes collaboration, corporate responsibility, and a positive, inclusive work environment, aiming to develop breakthrough therapies to treat cancer and improve patient outcomes.
Industries
Nr. of Employees
medium (51-250)
ITeos Therapeutics
321 Arsenal St, Bldg 312, Suite 301, Watertown, MA 02472, United States
Products
Anti-TIGIT monoclonal antibody candidate (checkpoint inhibitor)
A human IgG1 monoclonal antibody program designed to antagonize the TIGIT immune checkpoint to reduce immunosuppression and enhance antitumor T-cell and NK-cell activity; being evaluated in combination regimens across multiple cancer indications and clinical phases.
ENT1-targeting small-molecule oncology candidate
A small-molecule inhibitor program targeting ENT1 to block adenosine transport into T cells and restore T-cell proliferation and function in the tumor microenvironment; planned clinical evaluation including combinations with PD-1 inhibitors.
Anti-TREM2 monoclonal antibody candidate
An antibody program directed at TREM2 on myeloid cells aimed at inhibiting myeloid-driven immunosuppression and remodeling of the tumor microenvironment; being developed for monotherapy and combination testing in oncology indications.
Anti-TIGIT monoclonal antibody candidate (checkpoint inhibitor)
A human IgG1 monoclonal antibody program designed to antagonize the TIGIT immune checkpoint to reduce immunosuppression and enhance antitumor T-cell and NK-cell activity; being evaluated in combination regimens across multiple cancer indications and clinical phases.
ENT1-targeting small-molecule oncology candidate
A small-molecule inhibitor program targeting ENT1 to block adenosine transport into T cells and restore T-cell proliferation and function in the tumor microenvironment; planned clinical evaluation including combinations with PD-1 inhibitors.
Anti-TREM2 monoclonal antibody candidate
An antibody program directed at TREM2 on myeloid cells aimed at inhibiting myeloid-driven immunosuppression and remodeling of the tumor microenvironment; being developed for monotherapy and combination testing in oncology indications.
Services
Target identification and preclinical validation in tumor immunology to generate candidate therapeutics.
Design and operational execution of clinical studies across Phase 1–3, with emphasis on combination regimens and biomarker integration.
Evaluation of multiple biomarkers within clinical programs to guide combination choices and patient selection.
Preparation and dissemination of scientific posters, presentations and publications describing preclinical and clinical data.
Establishing collaborations with external organizations to advance discovery and clinical development.
Target identification and preclinical validation in tumor immunology to generate candidate therapeutics.
Design and operational execution of clinical studies across Phase 1–3, with emphasis on combination regimens and biomarker integration.
Evaluation of multiple biomarkers within clinical programs to guide combination choices and patient selection.
Preparation and dissemination of scientific posters, presentations and publications describing preclinical and clinical data.
Establishing collaborations with external organizations to advance discovery and clinical development.
Expertise Areas
- Immuno-oncology discovery
- Tumor microenvironment research
- Monoclonal antibody development
- Small-molecule oncology development
Key Technologies
- Monoclonal antibodies
- Small-molecule inhibitors
- Immune checkpoint targeting
- Adenosine-pathway modulation (ENT1 inhibition)
News & Updates
Board of Directors intends to cease operations – Company to focus efforts on selecting best path to deliver near-term…
GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data,…
Details about the 2022 AACR Poster for EOS-448.
Scientific publication discussing the mechanisms of action of a-TIGIT antagonist antibodies.
Details about the 2021 ASH Poster for EOS-448.
Presentation at the 2021 TIGIT Summit about EOS-448.
Board of Directors intends to cease operations – Company to focus efforts on selecting best path to deliver near-term…
GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data,…
Details about the 2022 AACR Poster for EOS-448.
Scientific publication discussing the mechanisms of action of a-TIGIT antagonist antibodies.
Details about the 2021 ASH Poster for EOS-448.
Presentation at the 2021 TIGIT Summit about EOS-448.